Aprea Therapeutics (APRE) Assets (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Assets of $47.6 million for Q1 2026, up 135.45% year-over-year from $20.2 million in Q1 2025, and up 198.82% quarter-over-quarter from $15.9 million in Q4 2025.
Aprea Therapeutics (APRE) Assets (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Assets for 9 consecutive years, with $47.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets rose 135.45% year-over-year to $47.6 million; the TTM figure through Mar 2026 stood at $47.6 million (up 135.45% YoY), while the FY2025 annual figure was $15.9 million, down 33.55% from the prior year.
- Assets climbed to $47.6 million in Q1 2026 per APRE's latest filing, from $15.9 million in the prior quarter.
- Across five years, Assets topped out at $50.3 million in Q1 2022 and bottomed at $14.3 million in Q3 2025.
- Historically, Assets has averaged $29.0 million across 5 years, with a median of $28.7 million in 2023.
- Annual changes were most pronounced in 2022 — Assets plunged 46.93% — and 2026, when it soared 135.45%.
- Aprea Therapeutics' Assets stood at $30.2 million in 2022, then slipped by 24.89% to $22.7 million in 2023, then climbed by 5.87% to $24.0 million in 2024, then plunged by 33.55% to $15.9 million in 2025, then jumped by 198.82% to $47.6 million in 2026.
- Business Quant data shows APRE's Assets at $47.6 million in Q1 2026, $15.9 million in Q4 2025, and $14.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - | 19.82 Bn |
| 10 | Aprea Therapeutics | 34.85 Mn | 34.85 Mn | - | 42.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 42.29 Mn |
| Mar 31, 2026 | 47.61 Mn |
| Dec 31, 2025 | 15.93 Mn |
| Sep 30, 2025 | 14.32 Mn |
| Jun 30, 2025 | 17.31 Mn |
| Mar 31, 2025 | 20.22 Mn |
| Dec 31, 2024 | 23.98 Mn |
| Sep 30, 2024 | 26.89 Mn |
| Jun 30, 2024 | 29.96 Mn |
| Mar 31, 2024 | 33.20 Mn |
| Dec 31, 2023 | 22.65 Mn |
| Sep 30, 2023 | 25.77 Mn |
| Jun 30, 2023 | 28.68 Mn |
| Mar 31, 2023 | 32.02 Mn |
| Dec 31, 2022 | 30.16 Mn |
| Sep 30, 2022 | 33.62 Mn |
| Jun 30, 2022 | 40.68 Mn |
| Mar 31, 2022 | 50.34 Mn |
| Dec 31, 2021 | 56.82 Mn |
| Sep 30, 2021 | 62.48 Mn |